New Benzothiazinone Derivatives and Their Use as Antibacterial Agents

Abstract

The present invention relates to novel benzothiazinone derivatives and their use as antibacterial agents in infectious diseases of mammals (humans and animals) caused by bacteria, especially diseases like tuberculosis (TB) and leprosy caused by mycobacteria. The present invention aims at the generation of new compounds with activity against mycobacteria as potential new tuberculosis drugs to overcome problems concerning resistance and drug intolerance. The solution of the present invention is a compound of formula I wherein R1 to R6 are as defined in the specification.

Description

RELATEDNESS OF THE APPLICATION

The subject application is a continuation of co-pending U.S. Ser. No. 12/227,655, filed Feb. 25, 2009, which is a 35 USC §371 Application Serial No. PCT/EP2006/004942, filed May 24, 2006. Applicants hereby incorporate by reference in their entirety the foregoing applications, and all references cited or discussed herein.

BACKGROUND OF THE INVENTION

The present invention relates to novel benzothiazin derivatives and their use as antibacterial agents in infectious diseases of mammals (humans and animals) caused by bacteria, especially diseases like tuberculosis (TB) and leprosy caused by mycobacteria.

Thiazinone, there derivatives and their use as antibacterial agents, especially against mycobacteria (TB), laid open for public use in AR 24 25 67 A1, AU 37 04 400 A1, CA 13 22 551 C1 or EP 0 245 901 B1 for instance.

As known, there is a threadful worldwide increase in tuberculosis infections with mycobacteria which developed resistance against the available therapeutics (B. R. Bloom, J. L Murray, Tuberculosis: commentary on a reemergent killer Science 257, 1992, 1055-1064). Extremely dangerous is the development of multidrug resistant (MDR) mycobacteria. These are mycobacteria, resistant at least against two of the most active tuberculosis drugs, isoniazid and rifampicin, but also against streptomycin, pyranzinamid and ethambutol. The proportion of MDR-TB in some countries is already more than 20%. Together with the increased number of TB diseases generally, worldwide it causes about 3,000,000 deaths annually.

For the treatment of such diseases, like (TB) or leprosy there is an urgent need for new drugs with new mechanisms of actions, especially to overcome drug resistance and to overcome the known dramatic side effects of the available drugs.

SUMMARY OF THE INVENTION

The present invention aims at the generation of new compounds with activity against mycobacteria as potential new tuberculosis drugs to overcome problems concerning resistance and drug intolerance.

This aim has been solved by providing compounds of the formula I

Wherein R¹ and R² are, independently each from other, NO₂, CN, CONR⁷R⁸, COOR⁹, CHO, halogen, NR⁷R⁸, SO₂NR⁷R⁸, SR⁹, OCF₃, mono-, di or trifluoromethyl;

R³ and R⁴ are, independently each from other, H, a saturated or unsaturated, linear or branched aliphatic radical having 1-7 chain members, cycloalkyl having 3-6 carbon atoms, benzyl, SR⁹, OR⁹;

R⁵ and R⁶ are, independently each from other, a saturated or unsaturated, halogenated or unhalogenated, linear or branched aliphatic radical having 1-8 chain members, cycloalkyl having 3-6 carbon atoms, phenyl, or R⁵ and R⁶ together represent a bivalent radical —(CR⁹₂)_m—, or R⁵ and R⁶ together represent bivalent radicals:

wherein m is 1-4, or represent bivalent radicals a saturated or unsaturated mono or polyheterocycles with heteroatoms N, S, O and substituted by (R¹⁰)x, wherein x is 1-4;

R⁷, R⁸ and R⁹ are, independently each from other H or a saturated or unsaturated, halogenated or unhalogenated, linear or branched aliphatic radical having 1-7 chain members, mono-, di or trifluoromethyl, halogen, phenyl, or R³ and R⁴ together represent a bivalent radical —(CH₂)_n— wherein n is 2-7;

R¹⁰ is H or a saturated or unsaturated, halogenated or unhalogenated, linear or branched aliphatic radical having 1-7 chain members, NO₂, NR⁷R⁸, CN, CONR⁷R⁸, COOR⁹, CHO, halogen, SO₂NR⁷R⁸, SR⁹, OR⁹, OCF₃, mono-, di or trifluoromethyl, benzyl or phenyl.

In a preferred embodiment the invention concerns compounds of the formula (I) selected from the group consisting of

• 2-(4-R⁵-4-R⁶-piperidin-1-yl)-8-nitro-6-trifluoromethyl-1,3-benzothiazin-4-one,
• 6-cyano-2-(4-R⁵-4-R⁶-piperidin-1-yl)-8-nitro-1,3-benzothiazin-4-one,
• 6-amido-2-(4-R⁵-4-R⁶-piperidin-1-yl)-8-nitro-1,3-benzothiazin-4-one,
• 2-(1,4-dioxa-8-azaspiro[4.5]dec-8-yl)-8-R¹-6-R²-1,3-benzothiazin-4-one,
• 2-(2-methyl-1,4-dioxa-8-azaspiro[4.5]dec-8-yl)-8-R¹-6-R²-1,3-benzothiazin-4-one,
• 2-[(2R)-2-methyl-1,4-dioxa-8-azaspiro[4.5]dec-8-yl]-8-R¹-6-R²-1,3-benzothiazin-4-one,
• 2-[(2S)-2-methyl-1,4-dioxa-8-azaspiro[4.5]dec-8-yl]-8-R¹-6-R²-1,3-benzothiazin-4-one,
• 2-(2,3-dimethyl-1,4-dioxa-8-azaspiro[4.5]dec-8-yl)-8-R¹-6-R²-1,3-benzothiazin-4-one,
• 2-(1,5-dioxa-9-azaspiro[5.5]undec-9-yl)-8-R¹-6-R²-1,3-benzothiazin-4-one,
  wherein R¹, R², R⁵ and R⁶ have the above meanings,

The present invention is even more particularly concerned with at least one compound selected from the group consisting of

• 2-(1,4-dioxa-8-azaspiro[4.5]dec-8-yl)-6,8-dinitro-1,3-benzothiazin-4-one,
• 2-(2-methyl-1,4-dioxa-8-azaspiro[4.5]dec-8-yl)-6,8-dinitro-1,3-benzothiazin-4-one,
• 2-(4,4-diethoxypiperidin-1-yl)-6,8-dinitro-1,3-benzothiazin-4-one, 7-methyl-2-(2-methyl-1,4-dioxa-8-azaspiro[4.5]dec-8-yl)-6,8-dinitro-1,3-benzothiazin-4-one,
• 2-(2-methyl-1,4-dioxa-8-azaspiro[4.5]dec-8-yl)-8-nitro-6-(trifluoromethyl)-1,3-benzothiazin-4-one,
• 2-(2,3-dimethyl-1,4-dioxa-8-azaspiro[4.5]dec-8-yl)-8-nitro-6-(trifluoromethyl)-1,3-benzothiazin-4-one,
• 2-(1,5-dioxa-9-azaspiro[5.5]undec-9-yl)-8-nitro-6-(trifluoromethyl)-1,3-benzothiazin-4-one,
• 2-(1,5-dioxa-9-azaspiro[5.5]undec-9-yl)-8-nitro-4-oxo-1,3-benzothiazine-6-carbonitrile,
• 2-(2-methyl-1,4-dioxa-8-azaspiro[4.5]dec-8-yl)-8-nitro-4-oxo-1,3-benzothiazine-6-carbonitrile,
• 8-amino-2-(2-methyl-1,4-dioxa-8-azaspiro[4.5]dec-8-yl)-4-oxo-1,3-benzothiazine-6-carbonitrile and
• 8-amino-2-(2-methyl-1,4-dioxa-8-azaspiro[4.5]dec-8-yl)-6-(trifluoromethyl)-1,3-benzo-thiazin-4-one.

For the synthesis of the aimed compounds we developed our original method of 1,3-benzothiazin-4-one synthesis with usage of dithiocarbamate derivatives as intermediate (method A). The classical method of 1,3-benzothiazin-4-one synthesis with usage of thiocyanate salts (method B) is usable too. Both are presented in the scheme below.

Surprisingly the compounds of the invention exhibit strong antibacterial activity, especially against mycobacteria with minimal inhibitory concentrations (MIC) in the range of 0.23 μg/ml->10 μg/ml for fast growing mycobacteria, of 0.195-1.56 μg/ml for M. tuberculosis, including multiresistant strains determined by the classical method and of 0.030 μg/ml for M. tuberculosis H37Rv determined by the Alamar Blue method. Surprisingly the compounds of the invention demonstrate a high level of selectivity for mycobacteria only which reduces the potential for adverse side effects dramatically.

The compounds of the invention are non-mutagenic at 5 mg/ml in the SOS chromotest.

The compounds of the invention are in vivo therapeutically active in the murine model of tuberculosis infection superior compared to the main antituberculosis drug isoniazid used as a positive control. 100% of mice survived. All control animals died until day 33.

The compound of the invention (especially compound no 2=example 1 in the embodiments), is non toxic after per os administration of doses ranging up to 2000 mg/kg was the compound was well endured by animals in the first and 24 next coming hours after introducing. During 7 days of investigations the compound 2 did not cause changes in general state and behavior of the mice, it did not affect motor and reflex activity, active and calm cycles, grooming, food consumption, there were no cases of animal death. LD₅₀ for compound 2 is >2000 mg/kg.

Thus, the compounds of the invention are useful for the treatment of tubercular infection and other mycobacterial infections, in humans and in animals.

Accordingly, the invention concerns pharmaceutical compositions comprising a compound of the formula I.

The invention relates furthermore to a compound of the formula I for use in a method for the treatment of bacterial infections in mammals. Preferred compounds of the formula I for use in such method are those specifically listed above.

The compounds of the invention are formulated for use by preparing a dilute solution or suspension in pharmaceutically acceptable aqueous, organic or aqueous-organic medium for topical or parenteral administration by intravenous, subcutaneous or intramuscular injection, or for intranasal application; or are prepared in tablet, capsule or aqueous suspension form with conventional excipients for oral administration or as suppositorium.

The compounds can be used in dosages from 0.001-1000 mg/kg body weight.

The examples which follow in the subsequent experimental part serve to illustrate the invention but should not be construed as a limitation thereof.

The structures of the compounds of the invention were established by modes of synthesis and elementary analysis, and by nuclear magnetic resonance and/or mass spectra, as well as by X-ray analysis.

DETAILED DESCRIPTION OF THE INVENTION

Starting Materials

Chemicals and solvents were purchased from Lancaster Synthesis (Lancashire, England) or from Aldrich (Sigma-Aldrich Company, St-Louis, US) and were used in the synthesis without additional purification. Melting points were determined according to the BP procedure and are uncorrected (Electrothermal 9001, GB). If analyses are indicated only by the symbols of the elements, analytical results are within ±0.3% of the theoretical values (Carlo-Erba 5500, Italy). NMR spectra were determined with a Varian Unity Plus 400 (USA). Shifts for ¹H NMR are reported in ppm downfield from TMS (δ). Mass spectra were obtained using a Finnigan SSQ-700 (USA) instrument with direct inject. Reactions and purity of compounds were controlled by TLC with usage Silicagel 60 F₂₅₄ aluminium sheets (Merck Co, Germany).

Example 1

2-(1,4-dioxa-8-azaspiro[4.5]dec-8-yl)-8-nitro-6-(trifluoromethyl)-1,3-benzothiazin-4-one, (compound 1)

Method A.

To a stirred 50 mL solution of 25% aqueous ammonia was added drop-wise a solution of 5 g of 2-chloro-3-nitro-5-trifluoromethylbenzoyl chloride (D. E Welch, R. R. Baron, B. A. Burton, J. Med. Chem. 12; 2; 1969; 299-303) in acetonitrile (10 mL) at −20° C. 10 min later, 50 ml of ethyl acetate was added. The organic phase was separated, washed twice in water, dried over Na₂SO₄, treated by activated carbon, filtered and concentrated in vacuum. The crude product was purified by crystallization from ethanol. The yield of 2-chloro-3-nitro-5-(trifluoromethyl)benzamide was 92%. mp 195-197° C. (methanol).

Anal. Calcd. for C₈H₄ClF₃N₂O₃: C, 35.78; H, 1.50; N, 10.43.

Found: C, 36.01; H, 1.53; N, 10.39.

0.5 g of 2,2-chloro-3-nitro-5-(trifluoromethyl)benzamide was dissolved in a 25 ml of ethanol. The reaction mixture was treated with of 0.5 g of 1,4-dioxa-8-azaspiro[4.5]decane-8-carbodithioic acid sodium salt dihydrate (Z. Ge, R. Li, T. Cheng, Synth. Commun., 29, 18, 1999, 3191-3196) and stored for 18 h at room temperature. It was then poured into 50 ml of cooled water and the resulting yellow precipitate was filtered off. Pure final product was obtained after recrystallization twice from ethanol. 2-(Aminocarbonyl)-6-nitro-4-(trifluoromethyl)phenyl-1,4-dioxa-8-azaspiro[4.5]decane-8-carbodithioate is light yellow crystalline solid. Yield 0.47 g %. mp 138-140° C.

Anal. Calcd. for C₁₁H₁₂N₄O₂S₂: C, 42.57; H, 3.57; N, 9.31; S, 14.21.

Found: C, 42.61; H, 3.67; N, 9.22; S, 14.30.

0.4 g of 2-(aminocarbonyl)-6-nitro-4-(trifluoromethyl)phenyl-1,4-dioxa-8-azaspiro[4.5]decane-8-carbodithioate was dissolved in a 25 ml of ethanol. The reaction mixture was treated with of 0.32 g of Na₂HPO₄×12H₂O and refluxed for 6 h. It was then cooled and light yellow precipitate was filtered off and washed by 30 ml methanol. Pure final product was obtained after recrystallization twice from ethanol. 2-(1,4-Dioxa-8-aza-spiro[4.5]dec-8-yl)-8-nitro-6-trifluoromethyl)-1,3-benzothiazin-4-one is light yellow crystalline solid. Yield 0.47 g %. mp 211-212° C.

R_f ((hexane-acetone; 2/1)-0.35

MS m/z 417 (M⁺).

¹H NMR (DMSO-d₆) δ 8.83 and 8.77 (two 1H, two s, 2CH), 3.80 (8H, broad s, N(CH₂CH₂)₂C), 2.02 (4H, broad s, OCH₂CH₂O) ppm.

Anal. Calcd. for C₁₆H₁₄F₃N₃O₅S: C, 46.04; H, 3.38; N, 10.07; S, 7.68.

Found: C, 45.94; H, 3.37; N, 10.09; S, 7.76.

Method B. The procedure in detail was the same as described in J. Imrich, P. Kristian, Coll. Czech. Chem. Commun., 47, 1982, 3268-3282; D. Koscik, P. Kristian, J. Gonda, E. Dandarova, Coll. Czech. Chem. Commun., 48, 1983, 3315-3328; D. Koscik, P. Kristian, O. Forgac, Coll. Czech. Chem. Commun., 48, 1983, 3427-3432; T. H. Cronin, H.-J. E. Hess, U.S. Pat. No. 3,522,247. Yield of 2-(1,4-dioxa-8-aza-spiro[4.5]dec-8-yl)-8-nitro-6-trifluoromethyl)-1,3-benzo-thiazin-4-one is 0.21%. The compound is identical by spectroscopical data to the compound synthesized by method A.

Example 2

2-(2-methyl-1,4-dioxa-8-azaspiro[4.5]dec-8-yl)-8-nitro-6-(trifluoro-methyl)-1,3-benzothiazin-4-one, (compound 2)

Following the procedure of Example 1. Light yellow crystalline solid.

Yield 54%. mp 192-3° C.

R_f (hexane-acetone; 2/1)-0.30.

MS m/z 431 (M^t).

¹NMR (DMSO-d₆) δ 8.81 and 8.77 (two 1H, two s, 2CH), 4.24 (1H, m, CH), 4.11 (1H, m, CH), 4.06 (4H, broad s, N(CH₂)₂), 3.47 (1H, t, CH), 3.27 (1H, s, CH), 1.80 (4H, broad d, C(CH₂)₂), 1.23 (3H, d, CH₃) ppm.

Anal. Calcd. for C₁₇H₁₆N₃O₅S: C, 47.33; H, 3.74; N, 9.74; S, 7.43.

Found: C, 47.36; H, 3.80; N, 9.87; S, 7.51.

Example 3

2-(1,4-dioxa-8-azaspiro[4.5]dec-8-yl)-6,8-dinitro-1,3-benzothiazin-4-one, (compound 4)

Following the procedure of Example 1 with usage of 2-hydroxy-3,5-dinitrobenzoic acid as starting material. Light yellow crystalline solid.

Yield 43%. mp 271-3° C. (EtOH/DMF).

R_f (hexane-acetone; 2/1)-0.25.

MS m/z 394 (M⁺).

¹H NMR (DMSO-d₆) δ 9.15 and 9.12 (two 1H, two s, 2CH), 3.86 (8H, broad s, N(CH₂CH₂)₂C), 2.97 (4H, broad s, OCH₂CH₂O) ppm.

Anal. Calcd. for C₁₅H₁₄N₄O₇S: C, 45.68; H, 3.58; N, 14.21; S, 8.13.

Found: C, 45.34; H, 3.56; N, 14.30; S, 7.98.

Example 4

2-(2-methyl-1,4-dioxa-8-azaspiro[4.5]decyl)-6,8-dinitro-1,3-benzothiazin-4-one, (compound 4)

Following the procedure of Example 1 with usage of 2-hydroxy-3,5-dinitrobenzoic acid as starting material. Yellow crystalline solid. Yield 57%. mp 139-142° C. (EtOH/DMF).

R_f(hexane-acetone; 2/1)-0.50.

MS m/z 408 (M⁺).

¹H NMR (DMSO-d₆) δ 9.08 and 9.11 (two 1H, two s, 2CH), 4.23 (1H, m, CH), 4.10 (1H, m, CH), 4.06 (4H, broad s, N(CH₂)₂), 3.43 (1H, t, CH), 3.27 (1H, s, CH), 1.80 (4H, broad d, C(CH₂)₂), 1.20 (3H, d, CH₃) ppm.

Anal. Calcd. for C₁₆H₁₆N₄O₇S: C, 47.06; H, 3.95; N, 13.72; S, 7.85.

Found: C, 46.87; H, 3.91; N, 13.57; S, 7.83.

Example 5

2-(2,3-dimethyl-1,4-dioxa-8-azaspiro[4.5]dec-8-yl)-8-nitro-6-(trifluoromethyl)-1,3-benzothiazin-4-one, (compound 5)

Following the procedure of Example 1 with usage of 2-hydroxy-3-nitro-5-trifluoromethylbenzoic acid as starting material. Light yellow crystalline solid. Yield 58%. mp 205-207° C. (EtOH/DMF).

R_f (hexane-acetone; 2/1)-0.55.

MS m/z 44522 (M⁺).

¹NMR (DMSO-d₆) δ 8.82 and 8.77 (two 1H, two s, 2CH), 3.86 (4H, broad c, N(CH₂)₂), 3.45-3.53 (2H, m, 2CH), 2.41 (4H, broad d, C(CH₂)₂), 1.13-1.17 (6H, m, 2CH₃) ppm.

Anal. Calcd. for C₁₈H₁₈F₃N₃O₅S: C, 48.54; H, 4.07; N, 9.43; S, 7.20.

Found: C, 48.66; H, 4.12; N, 9.32; S, 7.46.

Example 6

2-(4,4-diethoxypiperidin-1-yl)-6,8-dinitro-1,3-benzothiazin-4-one, (compound 6)

Following the procedure of Example 1 with usage as starting material 2-hydroxy-3,5-dinitrobenzoic acid. Yellow crystalline solid. Yield 32%. mp 179-181° C. (i-PrOH).

R_f(hexane-acetone; 2/1)-0.30.

MS m/z 424 (M⁺).

¹H NMR (DMSO-d₆) δ 9.08 and 9.11 (two 1H, two s, 2CH), 3.60-3.67 (4H, m, N(CH₂)₂) 2.11-2.08 (4H, m, C(CH₂)₂), 3.47 and 3.57 (two 2H, q, 2OCH₂), 1.16 (6H, t, 2CH₃), ppm.

Anal. Calcd. for C₁₇H₂₀N₄O₇S: C, 48.11; H, 4.75; N, 13.20; S, 7.56.

Found: C, 48.12; H, 4.73; N, 13.41; S, 7.67.

Example 7

2-(7,12-dioxa-3-azaspiro[5.6]dodec-3-yl)-6,8-dinitro-1,3-benzothiazin-4-one, (compound 7)

Following the procedure of Example 1 with usage as starting material 2-hydroxy-3,5-dinitrobenzoic acid. Yellow crystalline solid. Yield 51%. mp 193-195° C. (i-PrOH/DMF).

R_f (hexane-acetone; 2/1)-0.45.

MS m/z 422 (M⁺).

¹H NMR (DMSO-d₆) δ 8.97 and 9.16 (two 1H, two s, 2CH), 3.57-3.74 (8H, m, 4-CH₂), 1.93-2.35 (8H, m, 4-CH₂) ppm.

Anal. Calcd. for C₁₇H₁₈N₄O₇S: C, 48.34; H, 4.30; N, 13.26; S, 7.56.

Found: C, 48.21; H, 4.43; N, 13.30; S, 7.66.

Example 8

2-(1,4-dioxa-8-azaspiro[4.5]dec-8-yl)-7-methyl-6,8-dinitro-1,3-benzothiazin-4-one, (compound 8)

Following the procedure of Example 1 with usage as starting material 2-hydroxy-4-methyl-3,5-dinitrobenzoic acid. Yellow crystalline solid.

Yield 51%. mp 207-210° C. (i-PrOH/DMF).

R_f (hexane-acetone; 2/1)-0.30.

MS m/z 408 (M⁺).

¹H NMR (DMSO-d₆) δ 8.77 (1H, s, CH), 3.86 (8H, broad s, N(CH₂CH₂)₂C), 2.97 (4H, broad c, OCH₂CH₂O), 2.79 (3H, s, CH₃) ppm.

ppm.

Anal. Calcd. for C₁₆H₁₆N₄O₇S: C, 47.06; H, 3.95; N, 13.72; S, 7.85.

Found: C, 47.12; H, 4.01; N, 13.69; S, 7.94.

Example 9

2-(1,4-dioxa-8-azaspiro[4.5]dec-8-yl)-8-nitro-4-oxo-1,3-benzothiazine-6-carbonitrile, (compound 9)

To a stirred solution of 5 g (19 mmol) 2-hydroxy-5-iodobenzoic acid in 50 ml DMF was added by small portions dry 2.5 g (22 mmol) of CuCN (I). The reaction mixture was refluxed during 5 h, 100 ml of water and 50 ml ethylacetate were added. After it conc. Hydrochloric acid was added up to pH˜3 very carefully under good ventilation. The organic phase was separated, washed twice in water, dried over Na₂SO₄, treated by activated carbon, filtered and concentrated in vacuum. The crude product was purified by crystallization from water. The yield of 5-cyano-2-hydroxybenzoic acid was 71%. Following the procedure of Example 1. Yield 44%. mp 217-220° C. (EtOH/DMF).

R_f (hexane-acetone; 2/1)-0.50.

MS m/z 374 (M⁺).

¹H NMR (DMSO-d₆) δ 8.74 and 8.67 (two 1H, two s, 2CH), 3.41 (8H, broad s, N(CH₂CH₂)₂C), 2.93 (4H, broad s, OCH₂CH₂O) ppm.

Anal. Calcd. for C₁₆H₁₄N₄O₅S: C, 51.33; H, 3.77; N, 14.97; S, 8.57.

Found: C, 51.30; H, 3.84; N, 14.89; S, 8.62.

Example 10

2-(2-methyl-1,4-dioxa-8-azaspiro[4.5]dec-8-yl)-8-nitro-4-oxo-1,3-benzothiazine-6-carbonitrile, (compound 10)

Following the procedure of Example 9. Yellow crystalline solid. Yield 34%. mp 251-253° C. (EtOH/DMF).

R_f (hexane-acetone; 2/1)-0.40.

MS m/z 388 (M⁺).

¹H NMR (DMSO-d₆) δ 8.73 and 8.61 (two 1H, two s, 2CH), 4.23 (1H, m, CH), 4.11 (1H, m, CH), 4.07 (4H, broad s, N(CH₂)₂), 3.51 (1H, t, CH), 3.27 (1H, s, CH), 1.81 (4H, broad d, C(CH₂)₂), 1.22 (3H, d, CH₃) ppm ppm.

Anal. Calcd. for C₁₇H₁₆N₄O₅S: C, 52.57; H, 4.15; N, 14.43; S, 8.26.

Found: C, 52.42; H, 4.08; N, 14.50; S, 8.27.

Example 11

2-(1,5-dioxa-9-azaspiro[5.5]undec-9-yl)-8-nitro-4-oxo-1,3-benzothiazine-6-carbonitrile, (compound 11)

Following the procedure of Example 9. Yellow crystalline solid. Yield 40%. mp 230-232° C. (EtOH/DMF).

R_f (hexane-acetone; 2/1)-0.15.

MS m/z 388 (M⁺).

¹H NMR (DMSO-d₆) δ 8.74 and 8.61 (two 1H, two s, 2CH), 3.29-3.65 (6H, m, 3CH₂), 2.38 (4H, broad s, 2CH₂), 1.82-1.93 (4H, m, 2CH₂) ppm.

Anal. Calcd. for C₁₇H₁₆N₄O₅S: C, 52.57; H, 4.15; N, 14.43; S, 8.26.

Found: C, 52.52; H, 4.11; N, 14.59; S, 8.13.

Example 12

Determination of the in vitro inhibitory activity of the compounds of the invention against mycobacteria.

The antibacterial activities of the compounds against Mycobacterium smegmatis SG 987, M. aureum SB66, M. vaccae IMET 1010670 and M. fortuitum B were tested by determination of minimal inhibitory concentrations (MIC) by the micro broth dilution method in Mueller-Hinton broth (Difco) according to the NCCLS guidelines [National Committee for Clinical Laboratory Standards: Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; 5^th Ed.; Villanova, Ed.; Approved standard Document M7-A5. NCCLS, (2000)].

Activity against M. tuberculosis H37Rv was tested by the following method for determination of minimal inhibitory concentrations (MIC) and minimal bactericidal concentrations (MBC):

Strains were inoculated onto solid Lowenstein-Jensen medium. After 21 days, the cultures grown were used to prepare an inoculum suspension corresponding to 5×10⁸ microbial cells/ml). With 0.2 ml of that suspension tubes with 2 ml liquid Shkolnikova medium, containing corresponding concentrations of compounds under study—from 100.0 to 0.195 mg/ml, were inoculated. After 14 days of incubation at 37° C. the tubes with liquid medium were centrifuged for 15 min. at 3000 RPM.

After discarding the supernatant, the sediment was resuspended in 0.8 ml of sterile 0.9% NaCl. 0.1 ml of the suspension was used to prepare smears subsequently stained by the Ziehl-Neelsen method. The remaining sediment was inoculated in 0.2 ml volumes into three tubes with solid drug free Lowenstein-Jensen medium to determine minimal bactericidal concentrations (MBC). The results were read after 21-28 days of cultivation at 37° C. Controls were tubes cultured with test-strains not treated with the studied agents.

Minimal bactericidal concentration of drugs (MBC) was considered as the drug concentration completely inhibiting the growth of mycobacteria on the solid medium. The bacteriostatic effect (MIC) was characterized by the presence of only individual mycobacteria in the smear and a strong decrease in the number of colonies grown on solid media compared to the controls.

The results are presented in Tables 1 and 2.

TABLE 1
Antimicrobial activity of compounds as of the formula I determined
by minimal inhibitory concentrations MIC [μg/ml]
Compound.		M. smegmatis		M. vaccae	M. fortuitum
1	12.5	ng/ml	3.12	ng/ml	12.5	ng/ml
2	1.56	ng/ml	0.76	pg/ml	0.023	pg/ml
3	0.2	μg/ml	0.0015	μg/ml	0.006	μg/ml
4	0.2	μg/ml	0.003	μg/ml	0.003	μg/ml
5	6.25	ng/ml	0.078	ng/ml	0.078	ng/ml
6	>10	μg/ml	0.04	μg/ml	0.08	μg/ml
7	0.78	μg/ml	0.003	μg/ml	0.003	μg/ml
8	0.4	μg/ml	0.025	μg/ml	0.025	μg/ml
9	0.05	μg/ml	3.12	ng/ml	25	ng/ml
10	25	ng/ml	3.12	ng/ml	12.5	ng/ml
11	0.05	μg/ml	6.25	ng/ml	25	ng/ml

TABLE 2
Antimicrobial activity of compounds of the formula I against
Mycobacterium tuberculosis H37Rv and clinical isolates
6341 and 6374 as determined by minimal inhibitory concentrations
(MIC) and minimal bactericidal concentrations (MBC)
				MBC	MIC
		MBC	MIC	(μg/mL)	(μg/mL)
Strain	Compound	(μg/mL)	(μg/mL)	mean	mean
H37Rv	10	0.58	0.39	0.71	0.45
6341		0.78	0.58
6374		0.78	0.39
H37Rv	9	0.29	0.195	0.75	0.52
6341		1.17	0.78
6374		0.78	0.58
H37Rv	2	0.58	0.39	0.45	0.29
6341		0.39	0.29
6374		0.39	0.195
H37Rv	5	0.58	0.39	0.45	0.39
6341		0.39	0.39
6374		0.39	<0.39
H37Rv	1	0.58	0.39	1.75	1.17
6341		2.34	1.56
6374		2.34	1.56
H37Rv	Isoniazid	1.15	0.97	1.15	0.97
6341	(INH)	>100	>100	Not active, >100
6374		>100	>100	Not active, >100

Example 13

Determination of the in vivo inhibitory activity of the compounds of the invention against Mycobacterium tuberculosis in the murine TB model

To determine the chemotherapeutic efficacy we used BALB/c line mice with experimental hematogenously disseminated tuberculosis. The mice were obtained from the Central Animal Nursery of the Russian Academy of Medical Sciences. In this study we included mice after quarantine, standardized by weight (20-25 g) and male only. The mice were infected with a 2-week virulent culture of Mycobacterium tuberculosis H37Rv by intravenous injection (into tail vein) of the mycobacterial suspension at a dose of 5×10⁶ CFU (Colony Forming Unit) in 0.5 ml saline. All the experimental animals were divided into groups depending on the treatment regimen used (Table 3). Tested drug doses were selected based on the data from literature and on results of previous investigations.

TABLE 3
	No		Dose	Number of animals
	group	Compound	(mg/kg)	per group
	3	2	12	10
	4	2	25	10
	5	Isoniazid (INH)	25	10
	6	without treatment		10

Treatment was started the next day after infection. The drugs were introduced orally as suspension in carboxymethylcellulose/water with a small quantity PEG-400.

Chemotherapy was administered daily 6 times per week (except Sunday).

The animals were killed with ether narcosis. To determine the efficacy of each treatment regimen we registered macroscopical changes in parenchymal organs of the mice, growth of mycobacteria from pathologic material on solid media, as well as a bacterioscopical index of organ injury. We carried out a qualitative and quantitative analysis of macroscopical changes in the liver, spleen and lungs and calculated an injury index (using a four-score scale).

Macroscopical evaluation of the efficacy of each treatment regimen was expressed in the efficacy index, calculated using a formula.

$\mathrm{Efficacy}\mathrm{idex}=100\%-\frac{\begin{array}{c}\mathrm{Injury}\mathrm{index}\mathrm{of}\mathrm{the}\\ \mathrm{studied}\mathrm{group}\end{array}}{\begin{array}{c}\mathrm{Injury}\mathrm{index}\mathrm{of}\mathrm{the}\\ \mathrm{control}\mathrm{group}\end{array}}\times 100$

Microbiological examination included culture for determination of CFU in parenchymal organs. For this purpose, we homogenisated the right lung and separately the spleen with 6% sulfuric acid, centrifuged, washed by water and saline. The yield (about 0.5 mL) was diluted by 1.0 mL of saline and homogenisated. This suspension (0.5 mL) of test organs was diluted 100 and 1000 times by saline and was distributed on solid Finn-2 medium. The cultures were incubated at 37° C. for 1 months and read weekly starting from day 10. After 28 days CFU's were counted.

Data of macroscopical and microbiological examinations of parenchymal organs of mice which died during the experiment were also considered in the overall assessment of the experimental results which are represented in tables 4-6.

TABLE 4
Indexes of organ injury in mice and treatment efficacy
		Dose		Efficacy index
Group	Drug	(mg/kg)	Injury index	(%)
3	Compound 2	12	2.1	44.7
4	Compound 2	25	1.0	78
5	INH, Isoniazid	25	1.2	70.5
6	Control	—	3.8	—

TABLE 5
Results of microbiological examination of right lung and spleen of
experimental mice (42 days after inoculation of the culture medium)
			right lung	spleen
		Dose	Culture, without	Culture, without
Group	Compound	(mg/kg)	dilution CFU	dilution CFU
3	2	12	~60	~60
4	2	25	~35	~35
5	INH, Isoniazid	25	~40	~40
6	Control	—	>120	>120
			(total growth)	(total growth)

TABLE 6
Survival of animals
Day of	Group 3	Group 4	Group 5	Group 6
Treatment	Compound 2	Compound 2	INH	Control
1	10	10	10	10
2	10	10	10	10
3	10	10	10	10
4	10	10	10	10
5	10	10	10	10
6	10	10	10	10
7	10	10	10	10
8	10	10	10	10
9	10	10	10	10
10	10	10	10	10
11	10	10	10	10
12	10	10	10	10
13	10	10	10	9
14	10	10	10	9
15	10	10	10	9
16	10	10	10	9
17	10	10	10	9
18	10	10	10	9
19	10	10	10	9
20	10	10	10	8
21	10	10	10	8
22	10	10	10	8
23	10	10	10	8
24	10	10	10	8
25	10	10	10	5
26	10	10	10	4
27	100%	100%	100%	40%
All control animals died until day 33

Claims

1. A compound of formula (1):

or a salt thereof,

wherein R1 and R2 are, independently of each other, NO2, CN, CONR7R8, CHO, halogen, NR7R8, SO2NR7R8, SR9, OCF3, mono-, di- or trifluoromethyl;

R3 and R4 are, independently of each other, H, a saturated or unsaturated, linear or branched aliphatic radical having 1-7 chain members, cycloalkyl having 3-6 carbon atoms, benzyl, SR9, OR9;

R5 and R6 are, independently of each other, a saturated or unsaturated, linear or branched aliphatic radical having 1-8 chain members, cycloalkyl having 3-6 carbon atoms, phenyl, or R5 and R6 together represent a bivalent radical —(CR92)m-, or R5 and R6 together represent a bivalent radical:

wherein m is 1-4, or represent bivalent radicals, a saturated or unsaturated mono or polyheterocyles with heteroatoms N, S, O, and substituted by)(R10)x, where x is 1-4;

R7, R8 and R9 are, independently of each other, H or a saturated or unsaturated, halogenated or unhalogenated, linear or branched aliphatic radical having 1-7 chain members, mono-, di- or trifluoromethyl, halogen, phenyl;

R10 is H or a saturated or unsaturated, halogenated or unhalogenated, linear or branched aliphatic radical having 1-7 chain members, NO2, NR7R8, CN, CONR7R8, COOR9, CHO, halogen, SO2NR7R8, SR9, OR9, OCF3, mono-, di- or trifluoromethyl, benzyl or phenyl.

2. A 2-(2,3-R5R6-1,4-dioxa-8-azaspiro[4.5]dec-8-yl)-8-nitro-6-(trifluoro-methyl)-1,3-benzothiazin-4-one of the formula (1) according to claim 1, wherein R1 represents NO2, R2 is CF3, R3 and R4 are H, and R5 and R6 have the meanings given in claim 1.

3. A 2-(2,3-R5R6-1,4-dioxa-8-azaspiro[4.5]dec-8-yl)-8-nitro-4-oxo-1,3-benzothiazine-6-carbonitrile of the formula (1) according to claim 1, wherein R1 represents NO2, R2 is CN, R3 and R4 are H, and R5 and R6 have the meanings given in claim 1.

4. A 2-(2,3-R5R6-1,4-dioxa-8-azaspiro[4.5]dec-8-yl)-6,8-dinitro-4-oxo-1,3-benzothiazine of the formula (1) according to claim 1, wherein R1 and R2 represent NO2, R3 and R4 are H, and R5 and R6 have the meanings given in claim 1.

5. A 2-(2,3-R5R6-1,4-dioxa-8-azaspiro[4.5]dec-8-yl)-8-nitro-4-oxo-1,3-benzothiazine-6-carbamide of the formula (1) according to claim 1, wherein R1 represents NO2, R2 is CONH2, R3 and R4 are H, and R5 and R6 have the meanings given in claim 1.

6. A compound of the formula (1) according to claim 1 selected from the group consisting of:

2-(1,4-dioxa-8-azaspiro[4.5]dec-8-yl)-6,8-dinitro-1,3-benzothiazine-4-one,

2-(2-methyl-1,4-dioxa-8-azaspiro[4.5]dec-8-yl)-6,8-dinitro-1,3-benzothiazin-4-one,

2-(4,4-diethoxypiperidin-1-yl)-6,8-dinitro-1,3-benzothiazin-4-one,

7-methyl-2-(2-methyl-1,4-dioxa-8-azaspiro[4.5]dec-8-yl)-6,8-dinitro-1,3-benzothiazin-4-one,

2-(2-methyl-1,4-dioxa-8-azaspiro[4.5]dec-8-yl)-8-nitro-6-(trifluoromethyl)-1,3-benzothiazin-4-one,

2-(2,3-dimethyl-1,4-dioxa-8-azaspiro[4.5]dec-8-yl)-8-nitro-6-(trifluoromethyl)-1,3-benzothiazin-4-one,

2-(1,5-dioxa-9-azaspiro[5.5]undec-9-yl)-8-nitro-6-(trifluoromethyl)-1,3-benzothiazin-4-one,

2-(1,5-dioxa-9-azaspiro[5.5]undec-9-yl)-8-nitro-4-oxo-1,3-benzothiazine-6-carbonitrile,

2-(2-methyl-1,4-dioxa-8-azaspiro[4.5]dec-8-yl)-8-nitro-4-oxo-1,3-benzothiazine-6-carbonitrile,

8-amino-2-(2-methyl-1,4-dioxa-8-azaspiro[4.5]dec-8-yl)-4-oxo-1,3-benzothiazine-6-carbonitrile, and

8-amino-2-(2-methyl-1,4-dioxa-8-azaspiro[4.5]dec-8-yl)-6-(trifluoromethyl)-1,3-benzothiazin-4-one.

7. The compound of the formula (1) according to claim 1, wherein R5 and R6 are alkyl.

8. A pharmaceutical composition comprising a compound of the formula (1) according to claim 1.

9. A method of therapeutically or prophylactically treating tuberculosis in a mammal, comprising administering to the mammal a therapeutic or prophyltic dose of a pharmaceutical composition comprising a compound of formula (1)

Wherein R1 and R2 are, independently from each other, NO2, CN, CONR7R8, CHO, halogen, NR7R8, SO2NR7R8, SR9, OCF3, mono-, di- or trifluoromethyl;

R3 and R4 are, independently of each other, H, a saturated or unsaturated, linear or branched aliphatic radical having 1-7 chain members, cycloalkyl having 3-6 carbon atoms, benzyl, SR9, OR9;

R5 and R6 are, independently of each other, a saturated or unsaturated, linear or branched aliphatic radical having 1-8 chain members, cycloalkyl having 3-6 carbon atoms, phenyl, or R5 and R6 together represent a bivalent radical —(CR92)m—, or R5 and R6 together represent a bivalent radical:

wherein m is 1-4, or represent bivalent radicals, a saturated or unsaturated mono or polyheterocyles with heteroatoms N, S, O, and substituted by (R10)X, where x is 1-4;

R7, R8 and R9 are, independently of each other, H or a saturated or unsaturated, halogenated or unhalogenated, linear or branched aliphatic radical having 1-7 chain members, mono-, di- or trifluoromethyl, halogen, or phenyl, or R3 and R4 together represent a bivalent radical —(CH2)n— wherein n is 2-7;

R10 is H or a saturated or unsaturated, halogenated or unhalogenated, linear or branched aliphatic radical having 1-7 chain members, NO2, NR7R8, CN, CONR7R8, COOR9, CHO, halogen, SO2NR7R8, SR9, OR9, OCF3, mono-, di- or trifluoromethyl, benzyl or phenyl.